Patient death prompts pause in 2seventy bio's cancer therapy study.
TL;DR
Seattle Children's has paused a Phase I study of 2seventy bio's CAR-T cell therapy, SC-DARIC33, following the death of a patient who received the therapy at the second dose level. The therapy is being investigated in pediatric and young adult patients with acute myeloid leukemia, and the cause of the adverse event is currently under investigation.
Topics:businesshealthcare#acute-myeloid-leukemia#car-t-cell-therapy#healthcare#patient-death#phase-i-study#seattle-childrens
- Patient death leads Seattle Children's to pause study of 2seventy bio's CAR-T cell therapy Endpoints News
- Death triggers pause of 2seventy CAR-T cell therapy leukemia trial FierceBiotech
- 2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia Yahoo Finance
- 2SeventyBio's partner pauses cancer therapy study after patient death Reuters.com
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News